XOMA CorpFind Ratings Reports
XOMA CORP's gross profit margin for the second quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. XOMA CORP has average liquidity. Currently, the Quick Ratio is 1.45 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 34.65% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||0.44||2.54|
|Net Income ($mil)||-15.16||-23.76|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||34.3||50.96|
|Total Assets ($mil)||38.57||60.84|
|Total Debt ($mil)||46.52||48.0|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||-139.05||-110.4|
|Return on Assets||3.49||-110.43|
|Return on Equity||0.0||0.0|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||120.58||117.97|
|Div / share||0.0||0.0|
|Book value / share||-0.17||-0.27|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1066403.0||885860.0|
SELL. XOMA CORP's P/E ratio indicates a significant premium compared to an average of 42.78 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.84. Normally, for additional comaprison, we would look at the price-to-book ratio; however, this company's price-to-book ratio is negative making the value useless for comparisons. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount.
|XOMA 67.00||Peers 42.78||XOMA NM||Peers 21.27|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
XOMA is trading at a significant premium to its peers.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
XOMA's P/CF is negative making the measure meaningless.
|XOMA NM||Peers 31.52||XOMA 0.38||Peers 0.49|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
XOMA's ratio is negative making this valuation measure meaningless.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
XOMA trades at a discount to its peers.
|XOMA NM||Peers 10.46||XOMA 101.47||Peers 1.93|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
XOMA's P/B is negative making this valuation measure meaningless.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
XOMA is expected to have an earnings growth rate that significantly exceeds its peers.
|XOMA 1.48||Peers 690.55||XOMA 272.53||Peers 51.56|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
XOMA is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
XOMA has a sales growth rate that significantly exceeds its peers.